A New Digitized Method of the Compulsive Gnawing Test Revealed Dopaminergic Activity of Salvinorin A In Vivo [*]

 

 Buy Article Permissions and Reprints

Abstract

The compulsive gnawing (CG) test has been used for numerous years as an assay to determine the dopaminergic activity of various compounds. We developed a new method of quantification via a digitization step which allowed a more precise measurement of the gnawing activity. It was the aim of the present study to explore possible dopaminergic effects of salvinorin A (SA), the major active compound of Salvia divinorum, using the new digitized CG test. A group of experiments using male C57BL/6 mice were performed to validate the new method of quantification showing only significant increases of gnawing when the dopamine reuptake inhibitors buproprion (20 mg/kg, p. o.) and nomifensine (10 mg/kg, i. p.) were given concomitantly with apomorphine (10 mg/kg, i. p.). Different concentrations of the SA (1.0, 2.5, 5, and 10 mg/kg, i. p.) were tested with positive dopaminergic activity when administered with apomorphine which differed from the semisynthetic counterpart U-69593. Furthermore, the activity observed with SA was unsuccessfully antagonized by the κ-opioid receptor antagonist norbinaltorphimine (NorBNI; 10 and 20 mg/kg, i. p.), while the dopamine antagonist haloperidol did successfully block (0.06 mg/kg, i. p.) the gnawing activity seen with SA. Our data further strengthen the argument that salvinorin A is not a selective κ-opioid receptor agonist and is the first in vivo study that veers from salvinorin A acting solely like its synthetic counterparts. Furthermore, the digitized CG test system used in this study provides a new computational method to accurately detect behavior associated with dopaminergic neurotransmission.

1 Dedicated to Professor Dr. Dr. Adolf Nahrstedt on the occasion of his 70th birthday.

References

• 1 Canales J J, Gilmour G, Iversen S D. The role of nigral and thalamic output pathways in the expression of oral stereotypies induced by amphetamine injections into the striatum.  Brain Res. 2000;  856 176-183
  CrossrefPubMedGoogle Scholar
• 2 Karlsson R M, Hefner K R, Sibley D R, Holmes A. Comparison of dopamine D₁ and D₅ receptor knockout mice for cocaine locomotor sensitization.  Psychopharmacology (Berl). 2008;  200 117-127
  CrossrefPubMedGoogle Scholar
• 3 Taha E B, Redgrave P. Neuroleptic suppression of feeding and oral stereotypy following microinjections of carbachol into substantia nigra.  Neurosci Lett. 1980;  20 357-361
  CrossrefPubMedGoogle Scholar
• 4 Ther L, Schramm H. Apomorphine synergism (induced gnawing in mice) as a test for the differentiation of psychotropic substances.  Arch Int Pharmacodyn Ther. 1962;  138 302-310
  PubMedGoogle Scholar
• 5 Ernst A M. Mode of action of apomorphine and dexamphetamine on gnawing compulsion in rats.  Psychopharmacologia. 1967;  10 316-323
  CrossrefPubMedGoogle Scholar
• 6 Pedersen V. Potentiation of apomorphine effect (compulsive gnawing behaviour) in mice.  Acta Pharmacol Toxicol (Copenh). 1967;  25 (Suppl. 4) 63
  PubMedGoogle Scholar
• 7 De Feo G, Lisciani R, Pavan L, Samarelli M, Valeri P. Possible dopaminergic involvement in biting compulsion induced by large doses of clonidine.  Pharmacol Res Commun. 1983;  15 613-619
  CrossrefPubMedGoogle Scholar
• 8 Hedley L R, Wallach M B. Potentiation of apomorphine-induced gnawing in mice.  Prog Neuropsychopharmacol Biol Psychiatry. 1983;  7 47-56
  CrossrefPubMedGoogle Scholar
• 9 Ernst A M. Compulsive gnawing.  Pharmacol Ther. 1976;  2 173-184
  PubMedGoogle Scholar
• 10 Vogel H G. Drug discovery and evaluations: pharmacological assays, 2nd edition. Berlin; Springer-Verlag 2002: 567
  PubMedGoogle Scholar
• 11 Roth B L, Baner K, Westkaemper R, Siebert D, Rice K C, Steinberg S, Ernsberger P, Rothmann R B. Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist.  Proc Natl Acad Sci USA. 2002;  99 11934-11939
  CrossrefPubMedGoogle Scholar
• 12 Seeman P, Guan H C, Hirbec H. Dopamine D₂High receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil.  Synapse. 2009;  63 698-704
  CrossrefPubMedGoogle Scholar
• 13 Grundmann O, Phipps S M, Zadezensky I, Butterweck V. Salvia divinorum and salvinorin A: an update on pharmacology and analytical methodology.  Planta Med. 2007;  73 1039-1046
  Article in Thieme ConnectPubMedGoogle Scholar
• 14 Butelman E R, Harris T J, Kreek M J. The plant-derived hallucinogen salvinorin A produces kappa-opioid agonist-like discriminative effects in rhesus monkeys.  Psychopharmacology (Berl). 2004;  172 220-224
  CrossrefPubMedGoogle Scholar
• 15 Willmore-Fordham C B, Krall D M, McCurdy C R, Kinder D H. The hallucinogen derived from Salvia divinorum, salvinorin A, has kappa-opioid agonist discriminative stimulus effects in rats.  Neuropharmacology. 2007;  53 481-486
  CrossrefPubMedGoogle Scholar
• 16 Baker L E, Panos J J, Killinger B A, Peet M M, Bell L M, Haliw L A, Walker S L. Comparison of the discriminative stimulus effects of salvinorin A and its derivatives to U69,593 and U50,488 in rats.  Psychopharmacology (Berl). 2009;  203 203-211
  CrossrefPubMedGoogle Scholar
• 17 Braida D, Capurro V, Zani A, Rubino T, Vigano D, Parolaro D, Sala M. Potential anxiolytic- and antidepressant-like effects of salvinorin A, the main active ingredient of Salvia divinorum, in rodents.  Br J Pharmacol. 2009;  157 844-853
  CrossrefPubMedGoogle Scholar
• 18 Tang A H, Code R A. Discriminative stimulus properties of nalorphine in the rhesus monkeys.  J Pharmacol Exp Ther. 1983;  227 563-569
  PubMedGoogle Scholar
• 19 Siebert D J. Salvia divinorum and salvinorin A: new pharmacologic findings.  J Ethnopharmacol. 1994;  43 53-56
  CrossrefPubMedGoogle Scholar
• 20 Weber C C, Eckert G P, Mueller W E. Effects of antidepressants on the brain/plasma distribution of corticosterone.  Neuropsychopharmacology. 2006;  31 2443-2448
  CrossrefPubMedGoogle Scholar
• 21 Rojas-Corrales M O, Berrocoso E, Gibert-Rahola J, Mico J A. Antidepressant-like effect of tramadol and its enantiomers in reserpinized mice: comparative study with desipramine, fluvoxamine, venlafaxine and opiates.  J Psychopharmacol. 2004;  18 404-411
  CrossrefPubMedGoogle Scholar
• 22 Redolat R, Vidal J, Gomez M C, Carrasco M C. Effects of acute bupropion administration on locomotor activity in adolescent and adult mice.  Behav Pharmacol. 2005;  16 59-62
  CrossrefPubMedGoogle Scholar
• 23 Mague S D, Pliakas A M, Todtenkopf M S, Tomasiewicz H C, Zhang Y, Stevens W C, Jones R M, Portoghese P S, Carlezon W A. Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats.  J Pharmacol Exp Ther. 2003;  305 323-330
  CrossrefPubMedGoogle Scholar
• 24 Sotnikova T D, Beaulieu J M, Barak L S, Wetsel W C, Caron M G, Gainetdinov R R. Dopamine-independent locomotor actions of amphetamines in a novel acute mouse model of Parkinson disease.  PLoS Biol. 2005;  3 e271
  CrossrefPubMedGoogle Scholar
• 25 McKerchar T L, Fowler S C. Dissimilar effects of subchronic clozapine and haloperidol on operant lever pressing in C57BL/6J, BALB/cJ, and LP/J mice.  Behav Pharmacol. 2005;  16 585-589
  CrossrefPubMedGoogle Scholar
• 26 McCurdy C R, Sufka K J, Smith G H, Warnick J E, Nieto M J. Antinociceptive profile of salvinorin A, a structurally unique kappa opioid receptor agonist.  Pharmacol Biochem Behav. 2006;  83 109-113
  CrossrefPubMedGoogle Scholar
• 27 Moss D E, McMaster S B, Castaneda E, Johnson R L. An automated method for studying stereotyped gnawing.  Psychopharmacology (Berl). 1980;  69 267-269
  CrossrefPubMedGoogle Scholar
• 28 Christensen A V, Fjalland B, Nielsen I M. On the supersensitivity of dopamine receptors, induced by neuroleptics.  Psychopharmacology (Berl). 1976;  48 1-6
  CrossrefPubMedGoogle Scholar
• 29 Zhang Y, Butelman E R, Schlussman S D, Ho A, Kreek M J. Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonist actions at kappa opioid receptors.  Psychopharmacology (Berl). 2005;  179 551-558
  CrossrefPubMedGoogle Scholar
• 30 Thompson A C, Zapata A, Justice Jr J B, Vaughan R A, Sharpe L G, Shippenberg T S. Kappa-opioid receptor activation modifies dopamine uptake in the nucleus accumbens and opposes the effects of cocaine.  J Neurosci. 2000;  20 9333-9340
  PubMedGoogle Scholar
• 31 Gehrke B J, Chefer V I, Shippenberg T S. Effects of acute and repeated administration of salvinorin A on dopamine function in the rat dorsal striatum.  Psychopharmacology (Berl). 2008;  197 509-517
  CrossrefPubMedGoogle Scholar
• 32 Beerepoot P, Lam V, Luu A, Tsoi B, Siebert D, Szectman H. Effects of salvinorin A on locomotor sensitization to D2/D3 dopamine agonist quinpirole.  Neurosci Lett. 2008;  446 101-104
  CrossrefPubMedGoogle Scholar
• 33 Perreault M L, Graham D, Scattolon S, Wang Y, Szechtman H, Foster J A. Cotreatment with the kappa opioid agonist U69593 enhances locomotor sensitization to the D2/D3 dopamine agonist quinpirole and alters dopamine D2 receptor and prodynorphin mRNA expression in rats.  Psychopharmacology (Berl). 2007;  194 485-496
  CrossrefPubMedGoogle Scholar
• 34 Delfs J M, Kelley A E. The role of D1 and D2 dopamine receptors in oral stereotypy induced by dopaminergic stimulation of the ventrolateral striatum.  Neurosci Lett. 1990;  39 59-67
  PubMedGoogle Scholar
• 35 Dadkar N K, Dohadwalla A N, Bhattacharva B K. The involvement of serotoninergic and noradrenergic systems in the compulsive gnawing in mice induced by imipramine and apomorphine.  J Pharm Pharmacol. 1976;  28 68-69
  PubMedGoogle Scholar
• 36 Schoffelmeer A N, Hogenboom F, Mulder A H. Kappa1- and kappa2-opioid receptors mediating presynaptic inhibition of dopamine and acetylcholine release in rat neostriatum.  Br J Pharmacol. 1997;  122 520-524
  CrossrefPubMedGoogle Scholar

1 Dedicated to Professor Dr. Dr. Adolf Nahrstedt on the occasion of his 70th birthday.

Dr. Veronika Butterweck

Department of Pharmaceutics
University of Florida

Box 100494

Gainesville, FL 32610–0494

USA

Phone: + 1 35 22 73 78 25

Fax: + 1 35 22 73

Email: butterwk@cop.ufl.edu